Orexigen Therapeutics Inc.

350 articles about Orexigen Therapeutics Inc.

• Orexigen Announces Stockholder Approval Of All Proposals At 2016 Annual Meeting And Reverse Stock Split

  7/11/2016

• Orexigen Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  6/23/2016

• San Diego's Orexigen Names a New CFO and COO

  6/9/2016

• Orexigen Reports Favorable Markman Ruling In Contrave Patent Litigation

  6/8/2016

• Orexigen Founder And Former Chairman Eckard Weber Steps Down From Board

  5/27/2016

• Orexigen Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  5/26/2016

• Orexigen Appoints New Member Of Board Of Directors And Announces Senior Management Changes

  5/23/2016

• Orexigen Reports Business And Financial Results For The First Quarter Ended March 31, 2016

  5/5/2016

• Orexigen To Speak At The Bank of America Merrill Lynch 2016 Health Care Conference

  5/4/2016

• Orexigen Expands Commercial Leadership Team With Appointment Of Healthcare Industry Veteran Brian Longstreet As Senior Vice President Of Global Market Access And Development

  5/3/2016

• Orexigen Announces South Korean Approval Of Contrave (Naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients

  5/2/2016

• Orexigen Announces Upcoming Presentations At XIII International Congress On Obesity Hosted By The World Obesity Federation

  4/28/2016

• Orexigen Expands Commercial Capabilities With Appointment Of Beth Eastland, Vice President Of Sales, And Eight Additional New Employees

  4/25/2016

• Orexigen To Provide Business Update And Discuss First Quarter 2016 Financial Results On May 4, 2016

  4/21/2016

• Takeda Sells U.S. Rights to Contrave Back to Orexigen, Establishes New Business Units

  3/15/2016

• Orexigen To Host Conference Call At 8:30 A.M. Eastern Time Today To Discuss Acquisition Of U.S. Rights To Contrave (naltrexone HCl / bupropion HCl extended release) And Central And Eastern Europe Distribution Agreement With Valeant

  3/15/2016

• Orexigen Announces Commercialization And Distributorship Agreement With Valeant For Mysimba (naltrexone HCl / bupropion HCl prolonged release) For 18 Central And Eastern European Countries And Turkey

  3/15/2016

• Orexigen Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015

  2/26/2016

• Orexigen To Speak At The RBC Capital Markets 2016 Healthcare Conference

  2/19/2016

• Orexigen To Provide Business Update And Discuss Fourth Quarter And Full Year 2015 Financial Results On February 26, 2016

  2/19/2016